Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Oxaliplatin and Fluorouracil in Moderate-Risk Rectal Cancer
NCT04296240Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, capecitabine, fluorouracil in rectal cancer, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
oxaliplatincapecitabinefluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04296240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296240.